The CASP6 Knockout 786-O Polyclonal Cells are a CRISPR/Cas9-edited polyclonal cell population derived from the human 786-O renal cell carcinoma line, featuring targeted disruption of the CASP6 gene. This polyclonal knockout product provides a pooled population of edited cells, enabling loss-of-function studies while minimizing clonal artifacts. It is designed for researchers investigating apoptosis and cancer biology using a relevant renal carcinoma host background.
The 786-O cell line was established from a primary clear cell renal adenocarcinoma and harbors a bi-allelic mutation in the von Hippel-Lindau (VHL) tumor suppressor gene. This mutation leads to constitutive stabilization and activation of hypoxia-inducible factors (HIFs), recapitulating a key molecular feature of clear cell renal cell carcinoma (ccRCC). 786-O cells exhibit epithelial morphology and are widely employed as a model for VHL-dependent and -independent pathways in renal tumorigenesis, offering a genetically defined host for gene editing.
CASP6 functions as an executioner caspase downstream of initiator caspases (CASP8, CASP9, CASP10) and the cytochrome c/Apaf-1 apoptosome, as well as granzyme B. Upon activation, it cleaves critical substrates including lamin A/C, ??-tubulin, cytokeratins, PARP, huntingtin, and tau, orchestrating nuclear lamina disassembly, cytoskeletal collapse, and DNA repair inactivation. Its proteolytic activity is negatively regulated by inhibitor of apoptosis proteins such as XIAP. In the extrinsic pathway, death receptor signaling activates CASP8, which then processes CASP6 to promote lamin cleavage and apoptosis. In the intrinsic pathway, mitochondrial cytochrome c release triggers Apaf-1/CASP9 apoptosome formation, leading to CASP6 activation.
In the 786-O renal carcinoma context, CASP6 knockout is expected to impair apoptotic execution, potentially reducing sensitivity to chemotherapeutic agents that induce programmed cell death. The constitutive HIF activation in these cells may intersect with caspase-driven pathways, making this model valuable for dissecting crosstalk between hypoxia and apoptosis in ccRCC. Furthermore, CASP6 loss could reveal non-apoptotic roles of the protease in processes such as cell migration or cytoskeletal dynamics, expanding its utility in renal cancer research.
Key applications include apoptosis signaling studies, drug resistance screening, and CRISPR-based knockout validation. The polyclonal population supports assays such as Western blotting for cleaved CASP6, caspase activity measurements, TUNEL staining, annexin V apoptosis detection, immunofluorescence for lamin A/C integrity, and RT-qPCR for transcript confirmation. These tools enable investigation of how CASP6 disruption alters apoptotic responses and contribute to neurodegeneration modeling. For further information, please contact Ascent Research.
